ATE391179T1 - Variable fragmente von immunoglobulinen und ihre verwendung zu therapeutischen oder veterinären zwecken - Google Patents

Variable fragmente von immunoglobulinen und ihre verwendung zu therapeutischen oder veterinären zwecken

Info

Publication number
ATE391179T1
ATE391179T1 AT96913525T AT96913525T ATE391179T1 AT E391179 T1 ATE391179 T1 AT E391179T1 AT 96913525 T AT96913525 T AT 96913525T AT 96913525 T AT96913525 T AT 96913525T AT E391179 T1 ATE391179 T1 AT E391179T1
Authority
AT
Austria
Prior art keywords
fragments
immunoglobulins
therapeutic
veterinary purposes
variable fragments
Prior art date
Application number
AT96913525T
Other languages
English (en)
Inventor
Raymond Hamers
Serge Muyldermans
Original Assignee
Univ Bruxelles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bruxelles filed Critical Univ Bruxelles
Application granted granted Critical
Publication of ATE391179T1 publication Critical patent/ATE391179T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96913525T 1995-04-25 1996-04-25 Variable fragmente von immunoglobulinen und ihre verwendung zu therapeutischen oder veterinären zwecken ATE391179T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95400932A EP0739981A1 (de) 1995-04-25 1995-04-25 Variable Fragmente von Immunglobulinen-Verwendung zur therapeutischen oder veterinären Zwecken

Publications (1)

Publication Number Publication Date
ATE391179T1 true ATE391179T1 (de) 2008-04-15

Family

ID=8221483

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96913525T ATE391179T1 (de) 1995-04-25 1996-04-25 Variable fragmente von immunoglobulinen und ihre verwendung zu therapeutischen oder veterinären zwecken

Country Status (7)

Country Link
US (2) US7655759B2 (de)
EP (3) EP0739981A1 (de)
JP (1) JP4394162B2 (de)
AT (1) ATE391179T1 (de)
AU (1) AU5647896A (de)
DE (1) DE69637483T2 (de)
WO (1) WO1996034103A1 (de)

Families Citing this family (361)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0739981A1 (de) * 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable Fragmente von Immunglobulinen-Verwendung zur therapeutischen oder veterinären Zwecken
EP0937140B1 (de) * 1996-06-27 2007-09-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Antikörpermoleküle, die spezifisch mit dem aktiven Zentrum oder dem aktiven Spalt eines Zielmoleküls interagieren
EP1027439B1 (de) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalente antigenbindende proteine
EP1051493A2 (de) * 1998-01-26 2000-11-15 Unilever Plc Verfahren von antikörperteilen
ATE535154T1 (de) 1998-03-12 2011-12-15 Vhsquared Ltd Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben
EP0954978B1 (de) * 1998-03-12 2011-11-30 VHsquared Limited Produkten die inaktivierte Hefen oder Schimmel enthalten, die auf ihrer Aussenoberfläche aktive Antikörper haben
GB2400558B (en) * 1999-09-10 2004-12-15 Pasteur Institut Passive immunisation against bacillus anthracis
FR2798291B1 (fr) * 1999-09-10 2005-01-14 Pasteur Institut Compositions acellulaires immunogenes et compositions acellulaires vaccinales contre bacillus anthracis
AU2001268855A1 (en) 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
ATE352040T1 (de) 2000-11-17 2007-02-15 Univ Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
ES2368623T3 (es) * 2000-12-13 2011-11-18 Bac Ip B.V. Matrices de proteína de dominios variables de inmunoglobulina de cadena pesada de camilidae.
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
EP1461085A2 (de) * 2002-01-03 2004-09-29 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunokonjugate zur behandlung von tumoren
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
EP1558645B1 (de) * 2002-11-08 2011-07-27 Ablynx N.V. Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
CA2505326A1 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
MXPA05006043A (es) 2003-01-10 2006-01-30 Ablynx Nv Polipeptidos terapeuticos, homologos de los mismos, fragmentos de los mismos y para uso al modular la agregacion mediada de plaquetas.
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
EP2330120A3 (de) 2004-06-02 2011-11-16 AdAlta Pty Ltd Bindende Teile basierend auf Hai-IgNAR-Domänen
EP1978032A3 (de) 2004-07-22 2009-02-18 Erasmus University Medical Center Rotterdam Bindungsmoleküle
GB2416768A (en) * 2004-07-22 2006-02-08 Univ Erasmus Heavy chain immunoglobulin complexes
EP1814917A2 (de) * 2004-10-13 2007-08-08 Ablynx N.V. Anti-amyloid-beta-antikörper aus kameliden und diese enthaltende polypeptide für die behandlung und diagnose degenerativer nervenerkrankungen wie etwa morbus alzheimer
CN102336832A (zh) * 2004-11-25 2012-02-01 荷兰联合利华有限公司 重链和结构域抗体
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
ATE473446T1 (de) 2005-01-14 2010-07-15 Ablynx Nv Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind
ATE537188T1 (de) 2005-05-18 2011-12-15 Ablynx Nv Serumalbuminbindende proteine
SI2444424T1 (sl) 2005-05-20 2018-10-30 Ablynx N.V. Izboljšana protitelesa (TM) za zdravljenje z agregacijo posredovanih motenj
WO2006129828A2 (en) * 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Target substance capturing molecule
EP1912675B1 (de) 2005-07-25 2014-02-12 Emergent Product Development Seattle, LLC B-zell-verringerung mit cd37-spezifischen und cd20-spezifischen bindungsmolekülen
EP1915174A1 (de) * 2005-08-19 2008-04-30 Unilever N.V. Probiotische mikroorganismen und antikörper enthaltende nahrungsmittel
EP1999147A1 (de) * 2006-03-27 2008-12-10 Ablynx N.V. Medizinisches verabreichungsgerät für therapeutische proteine auf der basis von einzeldomänantikörpern
US20090074734A1 (en) 2006-05-02 2009-03-19 Actogenix N.V. Microbial intestinal delivery of obesity related peptides
US8409577B2 (en) 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
NZ576195A (en) 2006-10-10 2012-04-27 Az Univ Amsterdam Complement inhibition for improved nerve regeneration
WO2008074839A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
WO2008074840A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
SI2308514T1 (sl) 2007-03-23 2013-09-30 To-Bbb Holding B.V. Konjugati za prenos zdravila preko krvno-moĹľganske pregrade
WO2009004066A2 (en) 2007-07-03 2009-01-08 Ablynx N.V. Providing improved immunoglobulin sequences by mutating cdr and/or fr positions
JP5710978B2 (ja) 2007-11-08 2015-04-30 ネオジェニックス オンコロジー， インコーポレイテッド 結腸癌および膵臓癌に対する組み換えモノクローナル抗体および対応抗原
AU2008328785A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
EP2594584B1 (de) 2008-01-31 2015-07-15 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Molekül bestehend aus einer gentechnisch veränderten konstanten Domäne eines Antikörpers
CN101965362A (zh) 2008-03-05 2011-02-02 埃博灵克斯股份有限公司 新型抗原结合二聚体-复合物及其制备方法和应用
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
JP2011516520A (ja) 2008-04-07 2011-05-26 アブリンクス エン．ヴェー． Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
JP6013733B2 (ja) 2008-04-11 2016-10-25 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｃｄ３７免疫治療薬および二機能性化学療法薬とのその組合せ
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
GB0809474D0 (en) * 2008-05-27 2008-07-02 Prendergast Patrick T Comosition and method for teh assay and treatment of anthrax
WO2009150539A2 (en) * 2008-06-10 2009-12-17 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against androctonus autralis hector toxins
EP2346900A1 (de) * 2008-10-29 2011-07-27 Wyeth LLC Verfahren zur aufreinigung von einzeldomänantigenbindenden molekülen
CN104740631B (zh) 2008-10-29 2019-04-16 阿布林克斯公司 单域抗原结合性分子的制剂
WO2010063113A1 (en) * 2008-12-05 2010-06-10 University Of Guelph Anti-cobra toxin antibody fragments and method of producing a vhh library
AU2009329501B2 (en) 2008-12-19 2015-11-26 Ablynx N.V. Genetic immunization for producing immunoglobulins against cell-associated antigens such as P2X7, CXCR7 or CXCR4
DK2387583T3 (en) 2009-01-14 2019-01-14 Ablynx Nv PULMONAL ADMINISTRATION OF VARIABLE IMMUNGLOBULIN SINGLE DOMAINS AND CONSTRUCTIONS THEREOF.
EP2403873A1 (de) 2009-03-05 2012-01-11 Ablynx N.V. Neue antigenbindende dimerkomplexe, verfahren zur herstellung/vermeidung und anwendungen davon
EP2417163B1 (de) 2009-04-10 2019-02-27 Ablynx N.V. Verbesserte, gegen il-6r gerichtete aminosauresequenzen und polypeptide, die diese enthalten, zur behandlung von erkrankungen und storungen, die mit il-6r in zusammenhang stehen
WO2010125187A2 (en) 2009-04-30 2010-11-04 Ablynx Nv Method for the production of domain antibodies
HUE035773T2 (en) 2009-06-05 2018-05-28 Ablynx Nv Trivalent human airway giant cell virus (hrsv) nanotubes for preventing and / or treating respiratory infections
ES2804450T3 (es) 2009-07-10 2021-02-08 Ablynx Nv Método para la producción de dominios variables
US20120230918A1 (en) 2009-07-28 2012-09-13 Hoffmann-La-Roche Inc. Non-invasive in vivo optical imaging method
PL3438126T3 (pl) 2009-09-03 2021-03-08 Ablynx N.V. Stabilne formulacje polipeptydów i ich zastosowanie
EP2473529B1 (de) 2009-09-03 2016-02-10 Cancer Research Technology Limited Clec14a inhibitoren
UY32917A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
WO2011045079A1 (en) 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
EP2491056B1 (de) 2009-10-22 2021-09-15 Universiteit Twente Vhh zur anwendung bei gewebereperatur, organregeneration, organaustausch und gewebekonstruktion
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011098518A2 (en) 2010-02-11 2011-08-18 Ablynx Nv Delivery of immunoglobulin variable domains and constructs thereof
JP5951508B2 (ja) 2010-02-11 2016-07-13 アブリンクス エン．ヴェー． エアロゾルの調製のための方法及び組成物
TW201144437A (en) 2010-03-03 2011-12-16 Boehringer Ingelheim Int A-beta binding polypeptides
CA2794551A1 (en) 2010-03-26 2011-09-29 Westfaelische Wilhelms-Universitaet Muenster Substitute therapy for glucocorticoids
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
WO2013174537A1 (en) 2012-05-24 2013-11-28 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
EP2567234B1 (de) 2010-05-07 2018-09-19 F.Hoffmann-La Roche Ag Diagnoseverfahren zum Nachweis von Zellen ex vivo
US9932403B2 (en) 2010-05-20 2018-04-03 Ablynx Nv Biological materials related to HER3
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
EP3960865A1 (de) 2010-08-02 2022-03-02 Regeneron Pharmaceuticals, Inc. Mäuse, die bindeproteine mit vl-domänen produzieren
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
PL2632946T3 (pl) 2010-10-29 2018-06-29 Ablynx N.V. Sposób wytwarzania pojedynczych domen zmiennych immunoglobulin
TWI619811B (zh) 2010-11-08 2018-04-01 諾華公司 趨化細胞素受體結合多肽
US20140099264A1 (en) 2011-03-07 2014-04-10 F. Hoffman-La Roche Ag Means and methods for in vivo testing of therapeutic antibodies
WO2012120004A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
EP2691415B1 (de) 2011-03-28 2018-07-11 Ablynx N.V. Verfahren zur herstellung fester formulierungen mit variablen immunglobulin-einzeldomänen
AU2012234284B2 (en) 2011-03-28 2015-10-08 Ablynx Nv Bispecific anti-CXCR7 immunoglobulin single variable domains
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2707382B1 (de) 2011-05-09 2019-07-17 Ablynx NV Verfahren zur herstellung von variablen immunglobulin-einzeldomänen
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
CA2835340A1 (en) 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides
US9580480B2 (en) 2011-05-31 2017-02-28 Massachusetts Institute Of Technology Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
AU2012273928A1 (en) 2011-06-23 2014-02-06 Ablynx Nv Immunoglobulin single variable domains directed against IgE
EP4218933A1 (de) 2011-06-23 2023-08-02 Ablynx NV Serumalbuminbindende proteine
EP3311837A1 (de) 2011-09-23 2018-04-25 Ablynx NV Verlängerte hemmung der interleukin-6-vermittelten signalisierung
CN103889451B (zh) 2011-09-30 2016-06-29 埃博灵克斯股份有限公司 与C-Met相关的生物物质
CN104080909A (zh) 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
CN104520321A (zh) 2012-01-09 2015-04-15 斯克利普斯研究所 超长互补决定区及其用途
EP2802601B1 (de) 2012-01-09 2019-11-13 The Scripps Research Institute Humanisierte antikörper mit ultralangem cdr3s
IL311502A (en) 2012-02-27 2024-05-01 Ablynx Nv CX3CR1 binding polypeptides
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
JPWO2013180200A1 (ja) 2012-05-30 2016-01-21 中外製薬株式会社 標的組織特異的抗原結合分子
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
CN105073781A (zh) 2013-01-11 2015-11-18 加州生物医学研究所 牛融合抗体
JP6443344B2 (ja) 2013-01-30 2018-12-26 フエー・イー・ベー・フエー・ゼツト・ウエー スクリーニングおよび薬物開発のための新規キメラポリペプチド
WO2014122144A1 (en) 2013-02-05 2014-08-14 Engmab Ag BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA
EP2762496A1 (de) 2013-02-05 2014-08-06 EngMab AG Verfahren zur Auswahl von Antikörpern gegen BCMA
ES2745772T3 (es) 2013-02-05 2020-03-03 Vib Vzw Agentes de unión al receptor muscarínico de la acetilcolina y usos de los mismos
EP2968487B1 (de) 2013-03-15 2019-01-30 Vib Vzw Variable einzeldomänen des anti-makrophagen-mannose-rezeptors zur verwendung bei kardiovaskulären erkrankungen
CN113621057A (zh) 2013-04-02 2021-11-09 中外制药株式会社 Fc区变体
EP2789630A1 (de) 2013-04-09 2014-10-15 EngMab AG Bispezifische Antikörper gegen CD3e und ROR1
PL2992101T3 (pl) 2013-04-29 2019-05-31 Agrosavfe Nv Kompozycje agrochemiczne zawierające przeciwciała wiążące się ze sfingolipidami
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
ES2698375T3 (es) 2013-06-27 2019-02-04 Inst Nat Sante Rech Med Antagonistas de interleucina 15 (IL-15) y usos de los mismos para el tratamiento de enfermedades autoinmunes y enfermedades inflamatorias
US20160176943A1 (en) 2013-07-05 2016-06-23 Inserm (Insititut National De La Sante Et De La Recherche Medicale) Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
AU2014358191B2 (en) 2013-12-04 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
EP2883883A1 (de) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
CA2936728C (en) 2014-01-30 2023-06-20 Vib Vzw Opioid receptor binding agents and uses thereof
WO2015143414A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
EP3119811B1 (de) 2014-03-21 2019-10-30 Regeneron Pharmaceuticals, Inc. Vl antigen-bindende proteine mit unterschiedlichen bindungseigenschaften
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
EP3194976B1 (de) 2014-07-22 2020-04-01 Vib Vzw Verfahren zur auswahl von agenten, die proteinkomplexe stabilisieren
US20180036442A1 (en) 2014-07-29 2018-02-08 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
BR112017001782A2 (pt) 2014-07-29 2017-11-21 Univ Brussel Vrije fragmentos de anticorpo radiomarcados para uso na prevenção e/ou tratamento de câncer
CA2963692A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
AR102550A1 (es) 2014-11-05 2017-03-08 Agrosavfe Nv Planta transgénica que comprende un polinucleótido que codifica un dominio variable de anticuerpo de cadena pesada
WO2016097313A1 (en) 2014-12-19 2016-06-23 Ablynx N.V. Cysteine linked nanobody dimers
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
WO2016124568A1 (en) 2015-02-03 2016-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-rho gtpase conformational single domain antibodies and uses thereof
WO2016128549A1 (en) 2015-02-13 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
AU2016239948B2 (en) 2015-03-31 2022-03-17 Sorriso Pharmaceuticals, Inc. Polypeptides
CA2981098A1 (en) * 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
EP3294768B1 (de) 2015-05-13 2019-08-21 Ablynx N.V. T-zell-rekrutierende polypeptide auf basis von tcr-alpa/beta-reaktivität
PT3294319T (pt) 2015-05-13 2024-07-22 Ablynx Nv Polipéptidos de recrutamento de células t baseados na reatividade do cd3
EP3314260B1 (de) 2015-06-24 2021-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur detektion von protein-protein-interaktionen
CN108025093B (zh) 2015-07-17 2022-02-11 布鲁塞尔自由大学 用于在治疗癌症中使用的放射性标记的抗体片段
RS60030B1 (sr) 2015-08-03 2020-04-30 Engmab Sarl Monoklonska antitela protiv humanog antigena sazrevanja b ćelija (bcma)
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
KR20180053322A (ko) 2015-09-21 2018-05-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
NO2768984T3 (de) 2015-11-12 2018-06-09
CN108290943A (zh) 2015-11-13 2018-07-17 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白可变结构域
AU2016355569B2 (en) 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc CTLA4 binders
EA201891165A1 (ru) 2015-11-18 2018-11-30 Мерк Шарп И Доум Корп. Молекулы, связывающие pd1 и/или lag3
US11332519B2 (en) 2015-11-18 2022-05-17 Ablynx N.V. Serum albumin binders
AU2016360987A1 (en) 2015-11-27 2018-06-07 Ablynx Nv Polypeptides inhibiting CD40L
KR20180081825A (ko) 2015-12-04 2018-07-17 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드
WO2017134301A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Clec9a binding agents
EP3426278B1 (de) 2016-03-07 2024-01-03 Vib Vzw Einzeldomänenantikörper gegen cd20
EP3430058A4 (de) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. Multispezifische fab-fusionsproteine und verwendungen davon
EP3442993B1 (de) 2016-04-13 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und kits zum schnellen nachweis des escherichia-coli-o25b-st131-klons
EP3442562B1 (de) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd Ein il-22-dimer zur verwendung in der behandlung der nekrotisierenden enterokolitis
WO2017182605A1 (en) 2016-04-22 2017-10-26 Université Libre de Bruxelles A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
WO2017182603A1 (en) 2016-04-22 2017-10-26 Université Libre de Bruxelles A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
EP3452505A1 (de) 2016-05-02 2019-03-13 Ablynx NV Behandlung von rsv-infektion
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
EP3463452A1 (de) 2016-05-24 2019-04-10 Institut National de la Sante et de la Recherche Medicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur behandlung von nicht-kleinzelligem lungenkrebs (nsclc), der mit chronisch obstruktiver lungenerkrankung (copd) koexistiert
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
EP3512880A1 (de) 2016-09-15 2019-07-24 Ablynx NV Gegen makrophagenmigrationshemmenden faktor gerichte variable immunglobulin-einzeldomänen
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
ES2883678T3 (es) 2016-10-21 2021-12-09 Inst Nat Sante Rech Med Métodos para promover la respuesta de linfocitos T
CN110167964B (zh) 2016-11-02 2023-12-01 百时美施贵宝公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
BR112019010061A2 (pt) 2016-11-16 2019-08-13 Ablynx Nv polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
WO2018091720A1 (en) 2016-11-21 2018-05-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of metastases
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
IL310340A (en) 2016-12-07 2024-03-01 Ablynx Nv Immunoglobulin sites with a single variable enhance serum albumin binding
JP7300385B2 (ja) 2017-01-17 2023-06-29 アブリンクス エン．ヴェー． 改善された血清アルブミン結合剤
BR112019014599A2 (pt) 2017-01-17 2020-03-03 Ablynx N.V. Ligantes de albumina sérica melhorados
WO2018141964A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences Nv Targeted chimeric proteins and uses thereof
BR112019017853A2 (pt) 2017-02-28 2021-04-27 Vib Vzw Meios e métodos para liberação oral de proteína
CN106929513A (zh) * 2017-04-07 2017-07-07 东南大学 mRNA编码的纳米抗体及其应用
EP3612648A1 (de) 2017-04-18 2020-02-26 Université Libre de Bruxelles Biomarker und targets für proliferative erkrankungen
JP2020519261A (ja) 2017-05-11 2020-07-02 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 可変免疫グロブリンドメインのグリコシル化
UA125761C2 (uk) 2017-05-31 2022-06-01 Бьорінгер Інгельхайм Інтернаціональ Гмбх Поліпептид, який перешкоджає передачі wnt-сигналів у пухлинних клітинах
TW202417517A (zh) 2017-06-02 2024-05-01 德商麥克專利有限公司 與ｍｍｐ１３結合之免疫球蛋白
KR20200012935A (ko) 2017-06-02 2020-02-05 메르크 파텐트 게엠베하 Adamts 결합성 면역글로불린
WO2018220225A1 (en) 2017-06-02 2018-12-06 Ablynx Nv Aggrecan binding immunoglobulins
EP3630817A1 (de) 2017-06-02 2020-04-08 Merck Patent GmbH Polypeptide zur bindung von adamts5, mmp13 und aggrecan
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
AU2018301412A1 (en) 2017-07-11 2020-01-30 Alexion Pharmaceuticals, Inc. Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof
JP7241731B2 (ja) 2017-07-19 2023-03-17 フエー・イー・ベー・フエー・ゼツト・ウエー 血清アルブミン結合剤
CN111655340A (zh) 2017-09-20 2020-09-11 国家医疗保健研究所 用于调节自噬的方法和药物组合物
AU2018347521A1 (en) 2017-10-12 2020-05-07 Immunowake Inc. VEGFR-antibody light chain fusion protein
US11713356B2 (en) 2017-10-13 2023-08-01 Ose Immunotherapeutics Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
KR20200091400A (ko) 2017-10-31 2020-07-30 브이아이비 브이지더블유 신규한 항원-결합 키메라 단백질 및 이의 방법 및 용도
US20220135687A1 (en) 2017-12-28 2022-05-05 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against pd-l1
TW201930358A (zh) 2017-12-28 2019-08-01 大陸商南京傳奇生物科技有限公司 針對ｔｉｇｉｔ之單域抗體及其變異體
KR20200120641A (ko) 2018-01-15 2020-10-21 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
US20210054064A1 (en) 2018-01-24 2021-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale Antagonists of il-33 for use in methods for preventing ischemia reperfusion injusry in an organ
CA3090406A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
WO2019155041A1 (en) 2018-02-12 2019-08-15 Vib Vzw Gβγ COMPLEX ANTIBODIES AND USES THEREOF
WO2019158512A1 (en) 2018-02-13 2019-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prognosis and the treatment of glioblastoma
CN111655296A (zh) 2018-02-26 2020-09-11 埃博灵克斯股份有限公司 编码肽接头的经改良核苷酸序列
WO2019166622A1 (en) 2018-03-01 2019-09-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
WO2019175250A1 (en) 2018-03-13 2019-09-19 Smivet B.V. Single domain antibodies binding to tetanus neurotoxin
ES2960925T3 (es) 2018-03-23 2024-03-07 Univ Bruxelles Moléculas agonistas de la señalización de WNT
WO2019185723A1 (en) 2018-03-27 2019-10-03 Umc Utrecht Holding B.V. Targeted thrombolysis for treatment of microvascular thrombosis
TW202003567A (zh) 2018-03-30 2020-01-16 大陸商南京傳奇生物科技有限公司 針對lag-3之單一結構域抗體及其用途
WO2019193375A1 (en) 2018-04-04 2019-10-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fzd7 inhibitors for the treatment of retinal neovascularization
WO2019207030A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
AU2019280900A1 (en) 2018-06-09 2020-11-19 Boehringer Ingelheim International Gmbh DLL3-CD3 bispecific antibodies
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
EP3856772A1 (de) 2018-09-25 2021-08-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Verwendung von antagonisten von th17-zytokinen zur behandlung von bronchialer remodellierung bei patienten mit allergischem asthma
WO2020070062A1 (en) 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
US20210355216A1 (en) 2018-10-05 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and systems for controlling the agonistic properties of antibody variable domains by light
EP3636657A1 (de) 2018-10-08 2020-04-15 Ablynx N.V. Chromatographiefreies antikörperreinigungsverfahren
CN113508127A (zh) 2018-11-06 2021-10-15 阿尔萨泰克公司 神经变性疾病的基于细胞的基因疗法
EP3894438A1 (de) 2018-12-13 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuer anti-tau-svqivykpv-epitop-einzeldomänantikörper
US20230071889A1 (en) 2018-12-21 2023-03-09 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
KR20210107062A (ko) 2018-12-21 2021-08-31 오제 이뮈노테라프틱스 이작용성 항-PD-1/SIRPα 분자
KR20210107058A (ko) 2018-12-21 2021-08-31 오제 이뮈노테라프틱스 인간 pd-1에 대항하는 이작용성 분자
EP4059569A1 (de) 2019-01-03 2022-09-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verfahren und pharmazeutische zusammensetzungen zur verbesserung der cd8+-t-zellabhängigen immunantworten bei personen mit krebs
CA3126741A1 (en) 2019-01-15 2020-07-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
EP3943108A4 (de) 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha Antigen-bindendes molekül mit antigen-bindender domäne mit veränderlicher bindungsaktivität gegenüber antigen in abhängigkeit von mta und bibliothek zur gewinnung der antigen-bindenden domäne
KR20220012857A (ko) 2019-04-29 2022-02-04 콘포 테라퓨틱스 엔.브이. 트랜스맴브레인 단백질, 특히 gpcr과 함께 사용하기 위한 스크리닝 방법 및 검정
US20220289837A1 (en) 2019-04-30 2022-09-15 Vib Vzw Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
WO2020239934A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
WO2020239945A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
WO2020245663A1 (en) 2019-06-01 2020-12-10 Institut Pasteur Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection
CN114206938A (zh) 2019-06-20 2022-03-18 国家医疗保健研究所 抗蛋白酶nexin-1构象单域抗体及其用途
CA3144566A1 (en) 2019-06-21 2020-12-24 Sorriso Pharmaceuticals, Inc. Polypeptides
AU2020295767A1 (en) 2019-06-21 2022-02-17 Sorriso Pharmaceuticals, Inc. Compositions
WO2020254827A1 (en) 2019-06-21 2020-12-24 Vhsquared Limited Polypeptides
TW202128756A (zh) 2019-10-02 2021-08-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
EP4048703A1 (de) 2019-10-21 2022-08-31 Vib Vzw Nanoscheibenspezifische antigenbindende chimäre proteine
WO2021095031A2 (en) 2019-11-11 2021-05-20 Ibi-Ag Innovative Bio Insecticides Ltd. Insect control nanobodies and uses thereof
WO2021105438A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
JP2023504733A (ja) 2019-12-05 2023-02-06 オーエスイー・イミュノセラピューティクス 抗ｃｌｅｃ－１ａ抗体及びその抗原結合性断片
EP4069293A1 (de) 2019-12-06 2022-10-12 Ablynx N.V. Polypeptide mit variablen immunglobulin-einzeldomänen zur abzielung auf tnfa und ox40l
BR112022009799A2 (pt) 2019-12-06 2022-08-16 Ablynx Nv Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina alvejando tnfalfa e il-23
US20230040928A1 (en) 2019-12-09 2023-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof
AU2020400938A1 (en) 2019-12-09 2022-07-28 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ｏｓｅ免疫治療公司 包含il-7變體之雙官能分子
WO2021123360A1 (en) 2019-12-20 2021-06-24 Vib Vzw Nanobody exchange chromatography
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
EP4110794A1 (de) 2020-02-25 2023-01-04 Vib Vzw Allosterische modulatoren der leucinreichen repeat-kinase 2
EP4110826A4 (de) 2020-02-28 2024-08-14 Shanghai Henlius Biotech Inc Anti-cd137-konstrukte, multispezifischer antikörper und dessen verwendungen
CA3169939A1 (en) 2020-02-28 2021-09-02 Jie Xue Anti-cd137 construct and use thereof
JP2023519967A (ja) 2020-03-30 2023-05-15 アブリンクス・エヌ・フェー 多価免疫グロブリン単一可変ドメインの製造及び精製のための方法
WO2021198396A1 (en) 2020-03-31 2021-10-07 Biotalys NV Anti-fungal polypeptides
WO2021213435A1 (zh) 2020-04-22 2021-10-28 迈威(上海)生物科技股份有限公司 一种靶向人程序性死亡配体1(pd-l1)的单可变域抗体及其衍生物
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
EP3916088A1 (de) 2020-05-28 2021-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusionsproteine, die die sars-cov-2-3-clpro-katalytische domäne enthalten, und ihre verwendung zum screening von anti-sars-cov-2-mitteln
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
WO2021247769A1 (en) 2020-06-02 2021-12-09 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
KR20230025005A (ko) 2020-06-17 2023-02-21 얀센 바이오테크 인코포레이티드 만능 줄기세포의 제조를 위한 재료 및 방법
AU2021299932A1 (en) 2020-06-29 2023-02-02 Assistance Publique-Hôpitaux De Paris (Aphp) Anti-protein S single-domain antibodies and polypeptides comprising thereof
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
CN116783215A (zh) 2020-07-29 2023-09-19 当康生物技术有限责任公司 抗cd93构建体及其用途
CA3190516A1 (en) 2020-07-31 2022-02-03 Biotalys NV Expression host
WO2022063947A1 (en) 2020-09-24 2022-03-31 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
JP2023544124A (ja) 2020-09-25 2023-10-20 アブリンクス エン．ヴェー． Ｉｌ－１３およびｏｘ４０ｌを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
AU2021362007A1 (en) 2020-10-16 2023-06-22 Invisishield Technologies Ltd. Compositions for preventing or treating viral and other microbial infections
EP4255929A2 (de) 2020-12-02 2023-10-11 Vib Vzw Ltbr-agonist in kombinationstherapie gegen krebs
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
CA3201219A1 (en) 2020-12-04 2022-06-09 Mir Ali Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
EP4263606A1 (de) 2020-12-17 2023-10-25 Ose Immunotherapeutics Bifunktionelle anti-pd1/il-7 moleküle
AU2021399955A1 (en) 2020-12-18 2023-08-03 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
KR20230123497A (ko) 2020-12-18 2023-08-23 아블린쓰 엔.브이. IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드
MX2023007299A (es) 2020-12-18 2023-07-04 Ablynx Nv Polipeptidos de reclutamiento de celulas t basados en la reactividad de tcr alfa/beta.
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
CA3206125A1 (en) 2020-12-24 2022-06-30 Vib Vzw Murine cross-reactive human ccr8 binders
US20240076391A1 (en) 2020-12-24 2024-03-07 Oncurious Nv Human ccr8 binders
CA3206124A1 (en) 2020-12-24 2022-06-30 Vib Vzw Non-blocking human ccr8 binders
CN112920273B (zh) * 2020-12-30 2022-07-01 中国人民解放军海军军医大学 抗水母毒素纳米抗体cozo32、制备方法及用途
CN116917326A (zh) 2021-01-22 2023-10-20 博泰康医药公司 抗her-2/trop-2构建体及其用途
JP2024506020A (ja) 2021-02-05 2024-02-08 ブイアイビー ブイゼットダブリュ サルベコウイルス結合剤
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
CN117241804A (zh) 2021-02-17 2023-12-15 非营利性组织佛兰芒综合大学生物技术研究所 在癌症治疗中slc4a4的抑制
CN116964095A (zh) 2021-02-19 2023-10-27 沙裴隆有限公司 针对cd47的单域抗体及其用途
CA3211270A1 (en) 2021-02-19 2022-08-25 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
WO2022177393A1 (ko) 2021-02-19 2022-08-25 (주)샤페론 Pd-l1에 대한 단일 도메인 항체 및 이의 용도
WO2022177394A1 (ko) 2021-02-19 2022-08-25 (주)샤페론 Pd-l1 및 cd47에 대한 이중특이적 단일 도메인 항체 및 이의 용도
CN117321076A (zh) 2021-02-19 2023-12-29 美国卫生及公众服务部代表 中和SARS-CoV-2的单结构域抗体
EP4294927A2 (de) 2021-03-10 2023-12-27 Immunowake Inc. Immunmodulatorische moleküle und verwendungen davon
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
JP2024511424A (ja) 2021-03-25 2024-03-13 ダイナミキュア バイオテクノロジー エルエルシー 抗ｉｇｆｂｐ７構築物およびその使用
CA3213917A1 (en) 2021-04-09 2022-10-13 Nicolas Poirier New scaffold for bifunctional molecules with improved properties
US20240182572A1 (en) 2021-04-09 2024-06-06 Ose Immunotherapeutics Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
US20240261446A1 (en) 2021-05-17 2024-08-08 Université de Liège Anti-cd38 single domain antibodies in disease monitoring and treatment
US20240279334A1 (en) 2021-06-17 2024-08-22 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
WO2022269473A1 (en) 2021-06-23 2022-12-29 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
EP4359421A1 (de) 2021-06-23 2024-05-01 Vib Vzw Mittel und verfahren zur auswahl spezifischer bindemittel
CN117580865A (zh) 2021-06-29 2024-02-20 山东先声生物制药有限公司 Cd16抗体及其应用
CN113583125B (zh) * 2021-07-09 2022-09-20 苏州晟济药业有限公司 抗体以及包含其的结合剂、免疫吸附材料及其应用
EP4377352A2 (de) 2021-07-30 2024-06-05 Vib Vzw Kationunabhängige mannose-6-phosphat-rezeptorbindemittel für gezielten proteinabbau
EP4378954A1 (de) 2021-07-30 2024-06-05 Shandong Simcere Biopharmaceutical Co., Ltd. Bispezifischer anti-pvrig/anti-tigit-antikörper und anwendung
WO2023057601A1 (en) 2021-10-06 2023-04-13 Biotalys NV Anti-fungal polypeptides
CN118510534A (zh) 2021-11-09 2024-08-16 Ose免疫疗法 Clec-1配体的识别及其用途
WO2023089191A1 (en) 2021-11-22 2023-05-25 Ablynx N.V. Obtaining sequence information for target multivalent immunoglobulin single variable domains
EP4428156A1 (de) 2021-12-03 2024-09-11 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-bcma-nanokörper und verwendung davon
TW202342508A (zh) 2021-12-17 2023-11-01 比利時商艾伯霖克斯公司 包含靶向ＴＣＲαβ、ＣＤ３３和ＣＤ１２３的免疫球蛋白單可變結構域的多肽
WO2023125888A1 (zh) 2021-12-31 2023-07-06 山东先声生物制药有限公司 一种gprc5d抗体及其应用
WO2023135198A1 (en) 2022-01-12 2023-07-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
WO2023148291A1 (en) 2022-02-02 2023-08-10 Biotalys NV Methods for genome editing
WO2023148397A1 (en) 2022-02-07 2023-08-10 Vib Vzw Engineered stabilizing aglycosylated fc-regions
WO2023198806A1 (en) 2022-04-13 2023-10-19 Ose Immunotherapeutics New class of molecules for selective clearance of antibody
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023198851A1 (en) 2022-04-14 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
WO2023213751A1 (en) 2022-05-02 2023-11-09 Umc Utrecht Holding B.V Single domain antibodies for the detection of plasmin-cleaved vwf
WO2023217904A1 (en) 2022-05-10 2023-11-16 Institut National de la Santé et de la Recherche Médicale Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
WO2023222825A1 (en) 2022-05-18 2023-11-23 Vib Vzw Sarbecovirus spike s2 subunit binders
WO2023232826A1 (en) 2022-05-30 2023-12-07 Ose Immunotherapeutics Biomarkers of il7r modulator activity
TW202423482A (zh) 2022-06-08 2024-06-16 美商泰德治療公司 可電離陽離子脂質和脂質奈米顆粒、及其合成方法和用途
US20240109965A1 (en) 2022-06-14 2024-04-04 Ablynx N.V. Immunoglobulin single variable domains targeting t cell receptor
EP4299124A1 (de) 2022-06-30 2024-01-03 Universite De Montpellier Anti-mglur2-nanokörper zur verwendung als biomolekültransporter
EP4299125A1 (de) 2022-06-30 2024-01-03 Universite De Montpellier Anti-mglur2-biparatopische nanokörper und deren verwendungen
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
US20240117038A1 (en) 2022-07-18 2024-04-11 Ablynx N.V. Cx3cr1-binding compounds, methods and uses thereof
WO2024018426A1 (en) 2022-07-22 2024-01-25 Janssen Biotech, Inc. Enhanced transfer of genetic instructions to effector immune cells
US20240132624A1 (en) 2022-07-27 2024-04-25 Ablynx N.V. Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024028347A1 (en) 2022-08-01 2024-02-08 Ose Immunotherapeutics Heterodimeric fc-clec-1 fusion molecule and uses thereof
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
TW202417034A (zh) 2022-08-19 2024-05-01 大陸商億一生物醫藥開發（上海）有限公司 包含ｇ—ｃｓｆ之調配物及其用途
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
WO2024068944A1 (en) 2022-09-30 2024-04-04 Sanofi Anti-cd28 antibodies
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024105091A1 (en) 2022-11-15 2024-05-23 Imec Vzw Method and system for droplet manipulation
WO2024126363A1 (en) 2022-12-12 2024-06-20 Institut National de la Santé et de la Recherche Médicale Image-based high-content screening methods for identifying compounds targeting apicomplexan parasites
US20240200085A1 (en) 2022-12-15 2024-06-20 Aarhus Universitet Synthetic activation of multimeric transmembrane receptors
US20240209107A1 (en) 2022-12-19 2024-06-27 Sanofi Cd28/ox40 bispecific antibodies
US20240262923A1 (en) 2022-12-21 2024-08-08 Genzyme Corporation Anti-pd-1×4-1bb binding proteins
WO2024133937A1 (en) 2022-12-22 2024-06-27 Biotalys NV Methods for genome editing
WO2024145551A1 (en) 2022-12-29 2024-07-04 Biotalys NV Agrochemical compositions
WO2024141645A1 (en) 2022-12-30 2024-07-04 Biotalys N.V. Agglomerate
WO2024141638A1 (en) 2022-12-30 2024-07-04 Biotalys NV Self-emulsifiable concentrate
WO2024141641A2 (en) 2022-12-30 2024-07-04 Biotalys NV Secretion signals
WO2024156881A1 (en) 2023-01-27 2024-08-02 Vib Vzw CD8b-BINDING POLYPEPTIDES
WO2024156888A1 (en) 2023-01-27 2024-08-02 Vib Vzw Cd163-binding conjugates
WO2024165710A1 (en) 2023-02-09 2024-08-15 Seni-Preps B.V. Immunoglobulin single variable domains that inhibit urease and use thereof
WO2024168279A2 (en) 2023-02-10 2024-08-15 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen (psma) and methods for making and using the same
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
DK255887D0 (da) 1987-05-20 1987-05-20 Claus Koch Immunoassay
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5719267A (en) * 1989-10-31 1998-02-17 Ophidian Pharmaceuticals Inc. Clostridial toxin disease therapy
US5124249A (en) 1989-11-28 1992-06-23 Khan Rashid H Method for evaluating protection to bee venom
US6225447B1 (en) * 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
DE4122599C2 (de) * 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993022332A2 (en) * 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
GB2270076A (en) 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
US6765087B1 (en) * 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
EP1621554B2 (de) * 1992-08-21 2012-08-29 Vrije Universiteit Brussel Immunoglobuline ohne Leichtkette
US6838254B1 (en) * 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US6103521A (en) * 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
EP0739981A1 (de) * 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable Fragmente von Immunglobulinen-Verwendung zur therapeutischen oder veterinären Zwecken
BR9606706A (pt) * 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
ATE535154T1 (de) * 1998-03-12 2011-12-15 Vhsquared Ltd Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben
US6610472B1 (en) * 2000-10-31 2003-08-26 Genetastix Corporation Assembly and screening of highly complex and fully human antibody repertoire in yeast

Also Published As

Publication number Publication date
WO1996034103A1 (en) 1996-10-31
US20070009512A1 (en) 2007-01-11
AU5647896A (en) 1996-11-18
JP4394162B2 (ja) 2010-01-06
DE69637483D1 (de) 2008-05-15
JPH11503918A (ja) 1999-04-06
EP0822985B1 (de) 2008-04-02
EP1816198A1 (de) 2007-08-08
US20030088074A1 (en) 2003-05-08
US7655759B2 (en) 2010-02-02
EP0822985A1 (de) 1998-02-11
EP0739981A1 (de) 1996-10-30
DE69637483T2 (de) 2009-08-06

Similar Documents

Publication Publication Date Title
ATE391179T1 (de) Variable fragmente von immunoglobulinen und ihre verwendung zu therapeutischen oder veterinären zwecken
DK1087013T3 (da) Immunoglobuliner uden lette kæder
LTC0918797I2 (lt) Humanizuotas imunoglobulinas reaguojantis su alfa4beta7 integrinu
CY1107708T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
PT778891E (pt) Anticorpo monoclonal recombinante anti-rhesus d (d7c2)
WO1999023221A3 (en) Multivalent antigen-binding proteins
DK0637593T3 (da) Bispecifikke triggermolekyler, der genkender lymfocytantigen CD2 og tumorantigener
NO2006008I2 (no) Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
DE59010825D1 (de) Monoklonale Antikörper (MAK) gegen tumorassoziierte Antigene, ihre Herstellung und Verwendung
ATE495751T1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE69333484D1 (de) Umgestaltete monoklonale Antikörper gegen ein Immunglobulinisotyp
NO930406D0 (no) Spesifikke antistoffer mot aktiverte blodplater samt fremstilling

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties